Get the Stockscreener App
5.1792
3.53%
-0.2108
Precision Biosciences Inc stock is traded at $5.1792, with a volume of 67,765.
It is down -3.53% in the last 24 hours and up +11.35% over the past month.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
See More
Previous Close:
$5.39
Open:
$5.43
24h Volume:
67,765
Relative Volume:
0.15
Market Cap:
$39.28M
Revenue:
$52.29M
Net Income/Loss:
$-73.52M
P/E Ratio:
-7.8473
EPS:
-0.66
Net Cash Flow:
$-100.45M
1W Performance:
-7.64%
1M Performance:
+11.35%
6M Performance:
-50.00%
1Y Performance:
-59.12%
1-Day Range:
$5.00
$5.43
1-Week Range:
$5.00
$5.64
52-Week Range:
$3.61
$15.97
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences Inc
Sector
Industry
Phone
919-314-5512
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
5.2025 | 39.28M | 52.29M | -73.52M | -100.45M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.14 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.65 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
634.98 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.90 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.83 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-30-24 | Initiated | Guggenheim | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-09-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-27-20 | Resumed | BTIG Research | Buy |
| Apr-03-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-05-20 | Initiated | Stifel | Buy |
| Feb-25-20 | Initiated | William Blair | Outperform |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | H.C. Wainwright | Buy |
| Apr-22-19 | Initiated | Barclays | Overweight |
| Apr-22-19 | Initiated | Goldman | Buy |
| Apr-22-19 | Initiated | JP Morgan | Overweight |
| Apr-22-19 | Initiated | Jefferies | Buy |
View All
Precision Biosciences Inc Stock (DTIL) Latest News
The Latest Updates From the Gene-Editing Clinical Trials (February 2025) - CRISPR Medicine News
Long Term Trading Analysis for (DTIL) - Stock Traders Daily
Can This New Gene Editing Approach Transform Duchenne Muscular Dystrophy Treatment? - StockTitan
Precision BioSciences (DTIL) Stock Price, News & Analysis - MarketBeat
H.C. Wainwright Maintains Buy on Precision BioSciences Stock By Investing.com - Investing.com South Africa
Buy Rating for Precision BioSciences: Promising Clinical Data and Undervaluation Highlight Favorable Risk/Reward Scenario - TipRanks
H.C. Wainwright Maintains Buy on Precision BioSciences Stock - Investing.com India
Precision reports initial outcomes from Hepatitis B trial of PBGENE-HBV - Yahoo Finance
Precision BioSciences’ (DTIL) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Precision Bio gains on early Phase 1 data for Hep B candidate - MSN
Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate - AOL
Breakthrough in Hepatitis B Treatment: Precision BioSciences’ New Hope - Jomfruland.net
Precision Biosciences chief research officer sells $49,274 in stock - MSN
Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial - BioSpace
Precision Bio stock gains on Hep B drug data (DTIL:NASDAQ) - Seeking Alpha
Precision Biosciences Announces Initial Safety And Antiviral Activity Of Pbgene-Hbv - Marketscreener.com
Revolutionary Gene Therapy Achieves First-Ever ARCUS Success Against Hepatitis BWhat's Next? - StockTitan
Precision Biosciences' general counsel sells shares worth $42,765 - MSN
TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform - News-Medical.Net
Precision BioSciences announces board member's retirement - MSN
Precision BioSciences (DTIL) Poised for Growth with ARCUS Technology and Strategic Partnerships - HPBL
Precision BioSciences announces board member's retirement By Investing.com - Investing.com Canada
Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs - BioSpace
Precision BioSciences’ Cassie Gorsuch, PhD named CSO - TipRanks
Allogene Therapeutics vs. Precision BioSciences: A Deep Dive into Two Promising Gene Therapy Stocks – Market - HPBL
Precision Bio rises after gene editing data: BMO upgrades (update) - MSN
Precision Biosciences' general counsel sells shares worth $42,765 By Investing.com - Investing.com Canada
Precision Biosciences Inc Stock (DTIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Precision Biosciences Inc Stock (DTIL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Scimeca Dario | General Counsel and Secretary |
Jan 22 '25 |
Sale |
4.79 |
8,928 |
42,765 |
24,353 |
| Amoroso Michael | President and CEO |
Jan 21 '25 |
Sale |
4.67 |
36,838 |
172,033 |
107,087 |
| SMITH J. JEFFERSON | Chief Research Officer |
Jan 22 '25 |
Sale |
4.79 |
10,287 |
49,275 |
87,440 |
3.23%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):